Here’s a startling fact: patients with severe rheumatoid arthritis (RA) undergoing total ankle arthroplasty (TAA) face a heightened risk of postoperative wound complications—but a simple adjustment in their medication regimen could change the game entirely. And this is the part most people miss: a recent study reveals that modifying perioperative anti-rheumatic medications, as recommended for total hip and knee procedures, significantly reduces early wound complications in TAA patients. But here’s where it gets controversial—while guidelines exist for hip and knee surgeries, there’s a glaring gap for ankle procedures, leaving doctors to navigate this critical decision with limited direction.
Researchers compared two groups: one with modified perioperative anti-rheumatic medications (control group) and another without (uncontrolled group), tracking their progress for two years post-TAA. The challenge? Balancing the risk of complications from continued medication use against the risk of RA flare-ups if the medication is paused—a dilemma that still divides experts. Boldly put, this study dares to ask: Are we doing enough to protect TAA patients from preventable complications?
The trial included specific adjustments, such as tailored dosing and tapering of glucocorticoids like prednisone or dexamethasone, while NSAIDs and DMARDs were maintained without interruption. Interestingly, while pain relief during gait was comparable in both groups after two years, the real difference emerged in wound healing. Patients with medication modifications showed significantly better wound healing up to four weeks post-surgery (P=.003), while those without modifications experienced delayed healing (P=.039).
But don’t take this as the final word—the study’s non-randomized design and short follow-up period leave room for debate. Here’s the thought-provoking question for you: Should we wait for more definitive research, or should this study prompt immediate changes in clinical practice? The researchers advocate for larger, long-term studies to solidify these findings, but the implications are already sparking conversations in the medical community.
For now, this study serves as a critical reminder: even small adjustments in medication management can yield significant outcomes. What’s your take? Do these findings warrant a shift in how we approach TAA for RA patients? Share your thoughts in the comments—this is one discussion you won’t want to miss.
References
Yi JW, et al. J Clin Med. 2025 Oct 15;14(20):7280. doi: 10.3390/jcm14207280.
